

# Jessie Theuns

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/42011/publications.pdf>

Version: 2024-02-01

52  
papers

5,109  
citations

101543

36  
h-index

182427

51  
g-index

57  
all docs

57  
docs citations

57  
times ranked

7162  
citing authors

#	ARTICLE	IF	CITATIONS
1	Multi-centre evaluation of a comprehensive preimplantation genetic test through haplotyping-by-sequencing. <i>Human Reproduction</i> , 2019, 34, 1608-1619.	0.9	48
2	Agilent Technologies OnePGT solution: External verification on both blastomere and trophectoderm biopsies. <i>Reproductive BioMedicine Online</i> , 2019, 38, e11-e12.	2.4	0
3	Mutations in glucocerebrosidase are a major genetic risk factor for Parkinson's disease and increase susceptibility to dementia in a Flanders-Belgian cohort. <i>Neuroscience Letters</i> , 2016, 629, 160-164.	2.1	34
4	Progress in unraveling the genetic etiology of Parkinson disease in a genomic era. <i>Trends in Genetics</i> , 2015, 31, 140-149.	6.7	193
5	Global investigation and meta-analysis of the <i>C9orf72</i> (G <sub>4</sub> C <sub>2</sub> ) <sub>n</sub> repeat in Parkinson disease. <i>Neurology</i> , 2014, 83, 1906-1913.	1.1	56
6	Alpha-synuclein repeat variants and survival in Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 1053-1057.	3.9	14
7	Population-specific frequencies for <i>LRRK2</i> susceptibility variants in the genetic epidemiology of Parkinson's disease (GEO-PD) consortium. <i>Movement Disorders</i> , 2013, 28, 1740-1744.	3.9	30
8	A Pan-European Study of the <i>C9orf72</i> Repeat Associated with FTL: Geographic Prevalence, Genomic Instability, and Intermediate Repeats. <i>Human Mutation</i> , 2013, 34, 363-373.	2.5	247
9	A Multicenter Study of Glucocerebrosidase Mutations in Dementia With Lewy Bodies. <i>JAMA Neurology</i> , 2013, 70, 727.	9.0	374
10	Amyloid Pathology Influences A $\beta$ <sub>1-42</sub> Cerebrospinal Fluid Levels in Dementia with Lewy Bodies. <i>Journal of Alzheimer's Disease</i> , 2013, 35, 137-146.	2.6	45
11	A multi-centre clinico-genetic analysis of the <i>VPS35</i> gene in Parkinson disease indicates reduced penetrance for disease-associated variants. <i>Journal of Medical Genetics</i> , 2012, 49, 721-726.	3.2	94
12	DLB and PDD: a role for mutations in dementia and Parkinson disease genes?. <i>Neurobiology of Aging</i> , 2012, 33, 629.e5-629.e18.	3.1	73
13	Contribution of <i>VPS35</i> genetic variability to LBD in the Flanders-Belgian population. <i>Neurobiology of Aging</i> , 2012, 33, 1844.e11-1844.e13.	3.1	21
14	Large-scale replication and heterogeneity in Parkinson disease genetic loci. <i>Neurology</i> , 2012, 79, 659-667.	1.1	119
15	<i>Guanosine triphosphate cyclohydrolase 1</i> promoter deletion causes dopa-responsive dystonia. <i>Movement Disorders</i> , 2012, 27, 1451-1456.	3.9	11
16	The Genetics of Dementia With Lewy Bodies. <i>Archives of Neurology</i> , 2012, 69, 1113-8.	4.5	52
17	Locus-specific mutation databases for neurodegenerative brain diseases. <i>Human Mutation</i> , 2012, 33, 1340-1344.	2.5	414
18	Non-motor symptoms in a Flanders-Belgian population of 215 Parkinson's disease patients as assessed by the Non-Motor Symptoms Questionnaire. <i>American Journal of Neurodegenerative Disease</i> , 2012, 1, 160-7.	0.1	24

#	ARTICLE	IF	CITATIONS
19	Parkinson disease: Insights in clinical, genetic and pathological features of monogenic disease subtypes. <i>Journal of Chemical Neuroanatomy</i> , 2011, 42, 131-141.	2.1	65
20	Juvenile dystonia-parkinsonism and dementia caused by a novel ATP13A2 frameshift mutation. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 135-138.	2.2	54
21	GIGYF2 has no major role in Parkinson genetic etiology in a Belgian population. <i>Neurobiology of Aging</i> , 2011, 32, 308-312.	3.1	14
22	A large-scale genetic association study to evaluate the contribution of Omi/HtrA2 (PARK13) to Parkinson's disease. <i>Neurobiology of Aging</i> , 2011, 32, 548.e9-548.e18.	3.1	56
23	Role of sepiapterin reductase gene at the PARK3 locus in Parkinson's disease. <i>Neurobiology of Aging</i> , 2011, 32, 2108.e1-2108.e5.	3.1	23
24	Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. <i>Lancet Neurology</i> , The, 2011, 10, 898-908.	10.2	294
25	Comprehensive Genetic and Mutation Analysis of Familial Dementia with Lewy Bodies Linked to 2q35-q36. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 197-205.	2.6	20
26	Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. <i>Human Mutation</i> , 2010, 31, 763-780.	2.5	428
27	GIGYF2 in Parkinson's disease: Innocent until proven otherwise. <i>Neurobiology of Aging</i> , 2010, 31, 1072-1074.	3.1	4
28	Relative contribution of simple mutations vs. copy number variations in five Parkinson disease genes in the Belgian population. <i>Human Mutation</i> , 2009, 30, 1054-1061.	2.5	58
29	<i>APP</i> and <i>BACE1</i> miRNA genetic variability has no major role in risk for Alzheimer disease. <i>Human Mutation</i> , 2009, 30, 1207-1213.	2.5	52
30	Genetic variability in the mitochondrial serine protease <i>HTRA2</i> contributes to risk for Parkinson disease. <i>Human Mutation</i> , 2008, 29, 832-840.	2.5	107
31	Founder mutation p.R1441C in the leucine-rich repeat kinase 2 gene in Belgian Parkinson's disease patients. <i>European Journal of Human Genetics</i> , 2008, 16, 471-479.	2.8	47
32	Intraneuronal amyloid $\beta^2$ and reduced brain volume in a novel APP T714I mouse model for Alzheimer's disease. <i>Neurobiology of Aging</i> , 2008, 29, 241-252.	3.1	52
33	$\alpha$ -Synuclein gene duplications in sporadic Parkinson disease. <i>Neurology</i> , 2008, 70, 7-9.	1.1	13
34	A novel locus for dementia with Lewy bodies: a clinically and genetically heterogeneous disorder. <i>Brain</i> , 2007, 130, 2277-2291.	7.6	56
35	Alzheimer and Parkinson Diagnoses in Progranulin Null Mutation Carriers in an Extended Founder Family. <i>Archives of Neurology</i> , 2007, 64, 1436.	4.5	143
36	Genetic variant in the HSPB1 promoter region impairs the HSP27 stress response. <i>Human Mutation</i> , 2007, 28, 830-830.	2.5	47

#	ARTICLE	IF	CITATIONS
37	Promoter Mutations That Increase Amyloid Precursor-Protein Expression Are Associated with Alzheimer Disease. <i>American Journal of Human Genetics</i> , 2006, 78, 936-946.	6.2	173
38	APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy. <i>Brain</i> , 2006, 129, 2977-2983.	7.6	337
39	Mean age-of-onset of familial Alzheimer disease caused by presenilin mutations correlates with both increased A $\beta$ 242 and decreased A $\beta$ 40. <i>Human Mutation</i> , 2006, 27, 686-695.	2.5	306
40	Genetic risk and transcriptional variability of amyloid precursor protein in Alzheimer's disease. <i>Brain</i> , 2006, 129, 2984-2991.	7.6	76
41	Tau is central in the genetic Alzheimer's frontotemporal dementia spectrum. <i>Trends in Genetics</i> , 2005, 21, 664-672.	6.7	55
42	High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy. <i>Human Molecular Genetics</i> , 2005, 14, 3281-3292.	2.9	156
43	Linkage and Association Studies Identify a Novel Locus for Alzheimer Disease at 7q36 in a Dutch Population-Based Sample. <i>American Journal of Human Genetics</i> , 2005, 77, 643-652.	6.2	48
44	A novel presenilin 1 mutation associated with Pick's disease but not A $\beta$ amyloid plaques. <i>Annals of Neurology</i> , 2004, 55, 617-626.	5.3	210
45	Alzheimer-associated C allele of the promoter polymorphism -22C>T causes a critical neuron-specific decrease of presenilin 1 expression. <i>Human Molecular Genetics</i> , 2003, 12, 869-877.	2.9	45
46	The Gene Encoding Nicastrin, a Major $\gamma$ -Secretase Component, Modifies Risk for Familial Early-Onset Alzheimer Disease in a Dutch Population-Based Sample. <i>American Journal of Human Genetics</i> , 2002, 70, 1568-1574.	6.2	45
47	The TNFRSF6 gene is not implicated in familial early-onset Alzheimer's disease. <i>Human Genetics</i> , 2001, 108, 552-553.	3.8	6
48	Genetic association of the presenilin-1 regulatory region with early-onset Alzheimer's disease in a population-based sample. <i>European Journal of Human Genetics</i> , 1999, 7, 801-806.	2.8	49
49	Determination of the genomic organization of human presenilin 1 by fiber-FISH analysis and restriction mapping of cloned DNA. <i>Mammalian Genome</i> , 1999, 10, 410-414.	2.2	9
50	Genetic and physical characterization of the early-onset Alzheimer's disease AD3 locus on chromosome 14q24.3. <i>Human Molecular Genetics</i> , 1995, 4, 1355-1364.	2.9	27
51	Molecular genetic analysis of familial early-onset Alzheimer's disease linked to chromosome 14q24.3. <i>Human Molecular Genetics</i> , 1995, 4, 2363-2371.	2.9	171
52	Mutation analysis of the chromosome 14q24.3 dihydrolipoyl succinyltransferase (DLST) gene in patients with early-onset Alzheimer disease. <i>Neuroscience Letters</i> , 1995, 199, 73-77.	2.1	9